

Curriculum Vitae

Timothy A. Arlow, MD, PhD
Ophthalmic Associates

Current Position:

Physician

Ophthalmic Associates
Johnstown, PA
2018 – Present

Education/Training:

Undergraduate:

Syracuse University
Syracuse, NY
B.S. – Biomedical Engineering & Molecular Biology Double Major, Chemistry Minor
Honors: Cum Laude
2003-2007

Doctoral:

Doctor of Philosophy in Molecular Biology
Princeton University
Princeton, NJ
2009-2012

Doctor of Medicine

Rutgers – Robert Wood Johnson Medical School
New Brunswick, NJ
2007-2014

Post-Doctoral:

Internship

Reading Hospital
Reading, PA
2014-2015

Ophthalmology Residency:

Wills Eye Hospital
Philadelphia, PA
2014-2018

Licensure:

Medicine, Pennsylvania (MD-465219) – **Active**
ACLS, BLS Certified - Active

Awards/Honors:

Cum Laude – 2007
Ribbon for Highly Rated Paper – 2012
Gallo Award for Science Excellence – 2012
Alpha Omega Alpha National Honor Society Inductee - 2013
MD/PhD Student of the Year Award - 2014

Society Memberships:

American Academy of Ophthalmology – 2015
American Society of Cataract & Refractive Surgery – 2017
Pennsylvania Academy of Ophthalmology – 2015

Publications:

Arlow T., Capasso J, Levin A. Aniridia Case Series. *Review of Ophthalmology*; May 2016.

Arlow T., Sergott R. Neuromyelitis Optica Case Series. *Review of Ophthalmology*; November 2015.

Arlow T., Arepalli S., Flanders AE, Shields CL. Morning Glory Disc Anomaly with Chiari Type I Malformation. *The Journal of Pediatric Ophthalmology and Strabismus*, April 2014; 51:22-24.

Rogers JV, **Arlow T.**, E., Koo T., Rose MD. ER- associated SNAREs and Sey I p mediate nuclear fusion at two distinct steps during yeast mating. *Molecular Biology of the Cell*; December 2013; 24: 3896-908.

Zarbin MA, **Arlow T.**, Ritch R. Regenerative Nanomedicine for Vision Restoration. *Mayo Clinic Proceedings*; December 2013; 12: 1480-90.

Tennen RI, Haye JE, Wijayatilake HD, **Arlow T.**, Ponzio D., Gammie AE. Cell-cycle and DNA damage regulation of the DNA mismatch repair protein Msh2 occurs at the transcriptional and post- transcriptional level. *DNA Repair*; February 2013; 12: 97-109.

Arlow T., Scott K., Wagenseller A., Gammie AE. Proteasome inhibition rescues clinically significant unstable variants of the mismatch repair protein Msh2. *Proceedings of the National Academy of Sciences USA*; January 2013; 110: 246-51.

Presentations:

Arlow T., Pyfer M. Utilizing Anatomical Information from Femtosecond Laser Assisted Cataract Surgery (FLACS) to Better Predict IOL Power Calculations. Podium Presentation – ASCRS Symposium in Washington, D.C.; April 2018

Arlow T., Hufnagel E., Pyfer M. Utilizing Anatomical Information from Femtosecond Laser Assisted Cataract Surgery (FLACS) to Better Predict IOL Power Calculations. Podium Presentation – ESCRS Symposium in Lisbon, Portugal. October 2017

Arlow T., Hufnagel E., Pyfer M. Utilizing Anatomical Information from Femtosecond Laser Assisted Cataract Surgery (FLACS) to Better Predict IOL Power Calculations. Electronic Poster – ASCRS Symposium in Los Angeles, California. May 2017.

Arlow T., Gammie AE. The Proteasome Inhibitor Bortezomib rescues clinically identified unstable missense variants of the DNA mismatch repair protein Msh2. *Genetics Society of America “Yeast Genetics & Molecular Biology”* Conference, Princeton, NJ, in the Chromosome Dynamics: Mutagenesis/Repair Poster Session. August 2012

Arlow T., Gammie AE. The Proteasome Inhibitor Bortezomib rescues clinically identified unstable missense variants of the DNA mismatch repair protein Msh2. *Genetics Society of America “Model Organisms to Human Biology”* Conference, Washington, D.C., in the Cancer Genetics Session. June 2012.

Arlow T., Gammie AE. The Proteasome Inhibitor Bortezomib rescues clinically identified unstable missense variants of the DNA mismatch repair protein Msh2. *CINJ/NJCCR – “The Annual Retreat of Cancer Research in New Jersey”*, Piscataway, NJ – **Awarded the Gallo Award for Scientific Excellence**. May 2012.

Arlow T., Gammie AE. The Proteasome Inhibitor Bortezomib rescues clinically identified unstable missense variants of the DNA mismatch repair protein Msh2. 103rd Annual Meeting of the American Association for Cancer Research, Chicago, IL, in the DNA Repair/Genomic Stability Poster Session – **Awarded Ribbon for ‘Highly Rated Paper’**. April 2012.

Arlow T., Gammie AE. DNA mismatch repair and colorectal cancer: understanding pathogenic variants using yeast as a model system. *American Association for Cancer Research Special Conference on “Colorectal Cancer: Biology to Therapy”* Philadelphia, PA, in the Regulation of the Genome Session. October 2010.

Arlow T., Gammie AE. Clinically significant low steady-state level Msh2 missense variants display and increased turnover rate mediated by the ubiquitin-proteasome pathway. *Genetics Society of America “Yeast Genetics and Molecular Biology Meeting”* University of British Columbia, Vancouver, Canada, in the Keeping Chromosomes Together Session. August 2010.